HLA-A*26 and Susceptibility of Iranian Patients with Non-Hodgkin Lymphoma

Document Type: Original Article

Authors

1 Department of Medical Genetics, Shahid Beheshti University of Medical Sciences

2 Department of Medical Genetics, Faculty of Medical Science, Tarbiat Modares University

3 Taleghani Bone Marrow Transplantation Center

4 Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background: Non-Hodgkin lymphoma (NHL) includes a wide range of diseases with different clinical and biological features. NHL is usually presented as localized or generalized lymphadenopathy. It has been suggested that the HLA class I and II are associated with susceptibility to NHL. Different ethnic groups have been found to have different HLA class I and II alleles which affect NHL.
Objective: To evaluate the association of HLA class I and class II with Non-Hodgkin’s lymphoma in Iranian patients.
Methods: We performed a case-control genotyping study on 75 Iranian NHL patients who were selected from among the patients referred to the Bone Marrow Transplantation Department of Taleghani Hospital and 120 apparently healthy control subjects using the SSP-PCR by a commercial kit.
Results: Our results demonstrated that the HLA-A*26 (p: 0.026; OR: 8.5) and HLA-B*35 (p: 0.022; OR: 0.375) alleles had positive and negative associations with NHL disease, respectively. HLA-DRB1*13 allele showed decrease of frequency in patients in comparison with the controls, but it did not remain significant after correction.
Conclusions: Our results conclude that HLA-A*26 may represent as a genetic susceptibility factors in Iranian patients with Non-Hodgkin’s lymphoma, a finding which generally supports contribution of genetic factors in the etiology of this disorder. In addition, these results may be useful in designing a peptide based vaccine for the Iranian NHL patients with HLA-A*26.

Keywords